BioMimetic gains on FDA confirmation of foot and ankle fusions study
Shares of BioMimetic Therapeutics, Inc. (Nasdaq:BMTI) are gaining ground ahead of the bell after the developer of bio-active drug-device combination products said this morning that the Food & Drug Administration confirmed the status of its study for the treatment of foot and ankle fusions and said it should continue as originally designed.
Shares advanced 13%, or $1.35, to $11.34 ahead of the bell. For detailed price information and recent news stories about BioMimetic Therapeutics, click BMTI.
